 REDWOOD CITY, Calif., May 02, 2022 GLOBE NEWSWIRE -- Codexis, Inc. NASDAQ: CDXS, a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster presentations highlighting three of the Companys gene therapy programs using directed evolution to potentially improve treatment options for Hemophilia A and lysosomal storage diseases at the American Society of Gene and Cell Therapy ASGCT 25th Annual Meeting, taking place from May 16 to May 19, 2022, in Washington, D.C. and virtually. 